Syntaxin has reported that its partner, Allergan, has begun two Phase II trials to evaluate the safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868.

The trials will evaluate the drug candidate in patients with post-herpetic neuralgia nd overactive bladder.

AGN-214868 was discovered under the partnership using Syntaxin’s proprietary discovery platform.

Under the agreement, Allergan will be responsible for clinical development, marketing and sales of identified drug candidates, while Syntaxin will receive milestone payments and royalties on product sales.